Stay updated on SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial

Sign up to get notified when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the activity of tamibarotene in participants with acute myeloid leukemia or myelodysplastic syndrome.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:56.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying health conditions and prior treatments required for inclusion in the study. Previously, no information was provided in this section.
    Difference
    49%
    Check dated 2024-05-22T21:12:04.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:36:24.000Z thumbnail image

Stay in the know with updates to SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SY-1425 Biomarker-Directed Trial in AML/MDS Clinical Trial page.